SCHEMBL10296331

SCHEMBL10296331

COc1cc2c(OC)ncnc2cc1OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 1/20 0.68
IRAK4 Q9NWZ3 1/20 0.68
CSF1R P07333 2/20 0.60
PDGFRB P09619 1/20 0.60
FLT4 P35916 1/20 0.60
FLT3 P36888 1/20 0.60
KDM1A O60341 1/20 0.60
EGFR P00533 8/20 0.59
KDM4E B2RXH2 1/20 0.59
LMNA P02545 1/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59
LCK P06239 1/20 0.57
MAPK1 P28482 1/20 0.56
KIT P10721 2/20 0.55
RET P07949 2/20 0.54
KDR P35968 2/20 0.54
KIF5B P33176 1/20 0.54
ELANE P08246 1/20 0.52
ACHE P22303 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4023315 0.90 PDGFRB (0.75) IRAK1IRAK4CSF1RPDGFRBFLT4
SCHEMBL8810873 0.87 PDGFRB (0.68) IRAK1IRAK4CSF1RPDGFRBFLT4
SCHEMBL16281244 0.86 KDM1A (0.60) IRAK1IRAK4CSF1RPDGFRBKDM1A
SCHEMBL8815929 0.86 IRAK1 (0.59) IRAK1IRAK4CSF1RPDGFRBFLT4
SCHEMBL4359665 0.86 CSF1R (0.81) IRAK1IRAK4CSF1RPDGFRBFLT4
SCHEMBL6788900 0.85 IRAK1 (0.59) IRAK1IRAK4CSF1RPDGFRBFLT4
SCHEMBL297514 0.85 ENPP1 (0.68) IRAK1IRAK4KDM1AEGFRKDM4E
SCHEMBL14417895 0.85 KDM1A (0.58) IRAK1IRAK4KDM1AEGFRKDM4E
SCHEMBL4419576 0.85 IRAK1 (0.60) IRAK1IRAK4KDM1AEGFRKDM4E
SCHEMBL295891 0.85 ENPP1 (0.68) IRAK1IRAK4KDM1AEGFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211911-B2 Compounds as kinase inhibitors CHEN GUOQING PAUL (US) 2012-07-03 US disclosed
US-20100048599-A1 Compounds As Kinase Inhibitors CHEN GUOQING PAUL 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048599-A1 Compounds As Kinase Inhibitors MAP3K1, MAP3K5, MAP3K6 IRAK1 373/4885IRAK4 628/4885CSF1R 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.